Journal of Surgical Research
Volume 151, Issue 1 , Pages 28-32 , January 2009

The Significance of Arginase I Administration on the Survival of Mice Bearing NS-1 Myeloma Cells

  • Soo-Ray Wang, M.D., Ph.D.

      Affiliations

    • Department of Internal Medicine and The Institute of Medicine, Chung Shan Medical University and Chung Shan Medical University Hospital, Taichung, Taiwan
    • Corresponding Author InformationTo whom correspondence and reprint requests should be addressed at Department of Internal Medicine, Chung Shan Medical University Hospital, 110, Section 1, Chien-Kuo North Road, Taichung 402, Taiwan
    • ,
  • Stephen Hou, Ph.D.

      Affiliations

    • Laboratory Division, Clarient Inc., Aliso Viejo, California
    • ,
  • Amy Wang, M.D.

      Affiliations

    • Division of Nephrology/Hypertension, Department of Medicine, Northwestern University, Chicago, Illinois
    • ,
  • Yu-Jun Chang, B.A.

      Affiliations

    • Laboratory of Epidemiology and Biostatistics, Changhua Christian Hospital, Changhua, Taiwan
    • ,
  • Cheng-Tzu Liu, Ph.D.

      Affiliations

    • The Institute of Nutrition, Chung Shan Medical University, Taichung, Taiwan
    • ,
  • Gregory J. Tsay, M.D., Ph.D.

      Affiliations

    • Department of Internal Medicine and The Institute of Medicine, Chung Shan Medical University and Chung Shan Medical University Hospital, Taichung, Taiwan
    • ,
  • Chung-Cheng Wei, M.D., Ph.D.

      Affiliations

    • Department of Internal Medicine and The Institute of Medicine, Chung Shan Medical University and Chung Shan Medical University Hospital, Taichung, Taiwan

Received 17 September 2007

References 

  1. Wu CW, Chi CW, Lin EC, et al. Blood arginase level in patients with gastric cancer. J Clin Gastroenterol. 1994;18:84
  2. Wu CW, Chung WW, Chi CW, et al. Immunohistochemical study of arginase in cancer of the stomach. Virchows Arch. 1996;428:325
  3. Leu SY, Wang SR. Clinical significance of arginase in colorectal cancer. Cancer. 1992;70:733
  4. del Ara RM, Gonzalez-Polo RA, Caro A, et al. Diagnostic performance of arginase activity in colorectal cancer. Clin Exp Med. 2002;2:53
  5. Porembska Z, Luboinski G, Chrzanowska A, et al. Arginase in patients with breast cancer. Clin Chim Acta. 2003;328:105
  6. Gokmen SS, Aygit AC, Ayhan MS, et al. Significance of arginase and ornithine in malignant tumors of the human skin. J Lab Clin Med. 2001;137:34034
  7. Gokmen SS, Yoruk Y, Cakir E, et al. Arginase and ornithine, as markers in human non-small cell lung carcinoma. Cancer Biochem Biophys. 1999;17:125
  8. Yang H, Li G, Huang S, et al. Study of arginase activity in alveolar macrophages from patients with lung cancer. Hunan Yi Ke Da Xue Xue Bao. 1997;22:84
  9. Keskinege A, Elgun S, Yilmaz E. Possible implications of arginase and diamine oxidase in prostatic carcinoma. Cancer Detect Prev. 2001;25:76
  10. Chang CI, Liao JC, Kuo L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res. 2001;61:1100
  11. Li H, Meininger CJ, Hawker JR, et al. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab. 2001;280:E75
  12. Bronte V, Tosello V, Lowel M, et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol. 2003;170:270
  13. Wu CW, Chi CW, Ho CK, et al. Effect of arginase on splenic killer cell activity in patients with gastric cancer. Dig Dis Sci. 1994;39:1107
  14. Geldhof AB, van Ginderachter JA, Liu Y, et al. Ablation of NK cell function during tumor growth favors Type 2-associated macrophages, leading to suppressed CTL generation. Clin Dev Immunol. 2005;10:71
  15. Ikemoto M, Tanaka A, Fukuda Y, et al. Liver-type arginase in serum during and after liver transplantation: a novel index in monitoring conditions of the liver graft and its clinical significance. Clin Chim Acta. 1998;271:11
  16. Su HL, Huang MH, Yu CL, et al. The mechanisms of inhibitory effects of liver extract on lymphocyte proliferation. II. Inhibition on DNA, RNA, and protein syntheses and their relationship to the effects of metabolic inhibitors. Clin Exp Immunol (UK). 1988;72:228
  17. Su HL, Huang MH, Yu CL, et al. The mechanisms of inhibitory effects of liver extract on lymphocyte proliferation. III. The effects of arginase on DNA polymerase activities. Immunopharmacol (USA). 1989;18:135
  18. Huang MH, Yu CL, Han SH, et al. Evidence that an immunosuppressive protein from murine liver is arginase. Biochim Acta. 1990;49:179
  19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55
  20. Wang SR, Huang MH, Chang KL, et al. Characterization of murine liver-derived inhibitory protein. Scand J Immunol. 1990;31:85
  21. Ogata H, Miyoshi T, Itami J, et al. A clinical study of a multiregression analysis on the NK activity and related clinical factors in patients with lung cancer. Jpn J Cancer Clin. 1989;35:554
  22. Wang SR, Chen ML, Huang MH, et al. Plasma arginase concentration measured by an enzyme-linked immunosorbent assay (ELISA) in normal adult population. Clin Biochem. 1993;26:455
  23. Ikemoto M, Ishida A, Tsunekawa S, et al. Enzyme immunoassay of liver-type arginase and its potential clinical application. Clin. Chem. 1993;39:794

PII: S0022-4804(07)02393-1

doi: 10.1016/j.jss.2007.12.771

Journal of Surgical Research
Volume 151, Issue 1 , Pages 28-32 , January 2009

Article Tools

* Image Usage & Resolution